AIM17 Antibody

What is ADAM17 and why is it a significant target for antibody development?

ADAM17 (A Disintegrin And Metalloproteinase 17) is a membrane-bound enzyme that functions as a sheddase, cleaving the extracellular domains of various transmembrane proteins. It plays critical roles in inflammation, immune responses, and cancer progression by regulating the release of cytokines like TNF-α, growth factors, and cell surface receptors. The development of specific antibodies targeting ADAM17 enables researchers to understand its complex biological functions and explore its therapeutic potential in various disease contexts.

ADAM17 has been implicated in multiple pathophysiological processes, including inflammatory conditions and viral infections. Its ability to cleave numerous substrates makes it a complex but valuable research target .

How does MEDI3622 differ from other ADAM17 inhibitors?

MEDI3622 is a human IgG1 monoclonal antibody specifically targeting ADAM17. Unlike small molecule inhibitors that often affect multiple metalloproteinases simultaneously, MEDI3622 demonstrates high specificity for ADAM17. This specificity provides more definitive evidence of ADAM17's role in various biological processes and disease states.

The antibody's human IgG1 structure makes it amenable to clinical studies, distinguishing it from other research tools with less translational potential. This characteristic positions MEDI3622 as both a valuable research reagent and a potential therapeutic agent .

What are the optimal protocols for using ADAM17 antibodies in disease model research?

When implementing ADAM17 antibodies in disease model research, researchers should consider the following methodological approach:

• Animal model selection: For SARS-CoV-2 studies, the K18-hACE2 transgenic mouse model has proven effective. These mice express human ACE2, the receptor used by SARS coronaviruses for cellular entry.

• Antibody administration: Animals should be lightly anesthetized before antibody administration. For MEDI3622, a dosage of 10 mg/kg administered intraperitoneally has shown efficacy in inhibiting ADAM17 function.

• Control groups: Include appropriate controls such as saline-treated animals or isotype-matched antibody controls to distinguish specific ADAM17 inhibition effects from general antibody effects.

• Assessment parameters: Measure multiple parameters including weight change, clinical scores, tissue pathology, viral titers, and inflammatory markers to comprehensively evaluate the impact of ADAM17 inhibition .

How can researchers verify effective ADAM17 inhibition in their experimental systems?

Verification of ADAM17 inhibition requires multi-parameter assessment:

• TNF-α measurement: Quantify TNF-α levels in biological fluids (e.g., bronchoalveolar lavage fluid) as a direct indicator of ADAM17 inhibition, since TNF-α processing is a primary ADAM17 function.

• Substrate shedding analysis: Measure the cell surface expression of known ADAM17 substrates using flow cytometry. Effective ADAM17 inhibition should result in increased surface retention of these substrates.

• Functional readouts: Assess downstream inflammatory markers that are influenced by ADAM17 activity, such as inflammatory cytokine profiles and immune cell activation states.

• Histopathological examination: Examine tissue sections for inflammatory damage that would typically be associated with ADAM17-mediated processes .

What paradoxical effects have been observed with ADAM17 inhibition in viral infection models?

ADAM17 inhibition in viral infection models has revealed a complex duality of effects:

Treatment with MEDI3622 in SARS-CoV-2-infected K18-hACE2 mice resulted in significantly reduced morbidity, with treated animals appearing healthier and losing less weight than saline-treated controls. Histopathological examination revealed significantly less inflammatory damage in the lungs of antibody-treated mice.

Paradoxically, MEDI3622-treated mice exhibited significantly higher viral burdens in their lungs compared to controls. This suggests that while ADAM17 inhibition reduces harmful inflammation, it may simultaneously compromise certain aspects of antiviral immunity .

What mechanisms explain the reduced inflammatory damage but increased viral burden with ADAM17 inhibition?

The seemingly contradictory effects of ADAM17 inhibition can be explained through several interconnected mechanisms:

• Inflammation modulation: ADAM17 normally processes pro-inflammatory cytokines like TNF-α. Inhibition of this process with MEDI3622 significantly reduces TNF-α levels in bronchoalveolar lavage fluid, thereby dampening inflammatory cascades that lead to tissue damage.

• Antiviral immunity impact: The same inflammatory processes that damage host tissues may partially contribute to viral clearance. By inhibiting these processes, ADAM17 blockade may inadvertently impair certain aspects of antiviral immunity.

• Tissue preservation hypothesis: The healthier lung tissues in antibody-treated animals might eventually overcome higher viral titers through preserved functional capacity, similar to observations in other models where immunosuppressed animals eventually controlled viral infection despite initial higher viral loads .

How does ADAM17 inhibition impact NK cell function in antibody-based cancer therapies?

ADAM17 inhibition with MEDI3622 substantially enhances NK cell anti-tumor responses through several mechanisms:

• CD16A preservation: Human NK cells recognize tumor-bound antibodies via CD16A (FcγRIIIA). ADAM17 typically downregulates CD16A in a cis manner following NK cell stimulation. MEDI3622 blocks this ADAM17-mediated shedding of CD16A, preserving this critical receptor on the NK cell surface.

• Enhanced cytokine production: NK cells treated with MEDI3622 exhibit markedly increased production of IFNγ when exposed to antibody-bound tumor cells. This enhancement is observed across different tumor cell lines and therapeutic antibodies, and over various effector/target ratios.

• Specificity of effect: The augmented IFNγ release is reversed by function-blocking CD16A antibodies, confirming the mechanism involves CD16A preservation.

These findings position ADAM17 as a dynamic inhibitory checkpoint of CD16A function that can be targeted to potentially enhance the efficacy of tumor-targeting therapeutic antibodies .

What experimental evidence supports the role of CD16A shedding in limiting NK cell responses?

Several experimental approaches have conclusively demonstrated the limiting role of CD16A shedding in NK cell responses:

• Comparative NK92 studies: NK92 cells (a human NK cell line lacking endogenous FcγRs) expressing a non-cleavable version of CD16A release significantly higher levels of IFNγ than NK92 cells expressing equivalent levels of wildtype CD16A when engaging antibody-bound tumor cells.

• Antibody blocking experiments: The enhanced release of IFNγ by NK cells treated with MEDI3622 is reversed by a function-blocking CD16A antibody, confirming the CD16A-dependent mechanism.

• ADAM17 inhibition specificity: MEDI3622 effectively blocks ADAM17 function in NK cells and consistently produces increased IFNγ production across different experimental conditions, supporting the specificity of this effect .

What are the implications of combining ADAM17 inhibition with other therapeutic strategies?

The unique mechanism of ADAM17 inhibition opens several promising combinatorial approaches:

• Antiviral combination therapy: For COVID-19 treatment, combining MEDI3622 with approved antiviral drugs could potentially address both overt inflammation and high viral load simultaneously. This approach could provide superior outcomes by targeting the two major pathological components of severe viral infections.

• Cancer immunotherapy enhancement: Combining ADAM17 inhibitors with tumor-targeting antibodies could potentiate NK cell-mediated antibody-dependent cellular cytotoxicity by preserving CD16A expression, potentially improving clinical responses to therapeutic antibodies.

• Inflammatory disease management: For non-infectious inflammatory conditions, ADAM17 inhibition could provide more specific immunomodulation than broad-spectrum antiinflammatory agents, potentially offering better safety profiles for chronic treatment .

What insights from antibody design research could improve ADAM17-targeting strategies?

Recent advances in antibody design methodology offer several approaches to optimize ADAM17-targeting strategies:

• Epitope mapping and selection: Understanding the relationship between epitope binding and functional outcomes allows for rational selection of antibodies that target specific functional domains of ADAM17, potentially enabling selective inhibition of certain ADAM17 activities while preserving others.

• Computational approaches: Modern computational methods can predict antibody-antigen interactions and guide the design of antibodies with enhanced specificity profiles, potentially allowing for the development of ADAM17 antibodies with tailored substrate selectivity.

• High-throughput screening: Integration of high-throughput sequencing with downstream computational analysis enables the identification of different binding modes and associated ligand specificities, facilitating the design of antibodies with highly specific binding profiles .